ClearPoint Neuro, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. ClearPoint Neuro is a commercial-stage medical-device company focused on minimally invasive brain procedures, with activities spanning neurosurgical products and services for pharmaceutical and biotech partners developing biologics and drug delivery approaches.
Key financial results
Amounts below are in millions of dollars except per-share data.
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Total revenue | $5.03 | $4.03 |
| Gross profit / gross margin | $3.25 / 65% | $2.61 / 65% |
| Research and development | $2.53 | $1.56 |
| Sales and marketing | $1.85 | $1.58 |
| General and administrative | $2.73 | $1.66 |
| Operating loss | $(3.86) | $(2.18) |
| Net loss | $(3.96) | $(2.54) |
| Net loss per share, basic and diluted | $(0.17) | $(0.13) |
| Cash used in operating activities | $(4.27) | $(2.13) |
Liquidity and debt: Cash and cash equivalents were $49.66 million at March 31, 2022, down from $54.11 million at December 31, 2021. Current assets were $58.01 million and current liabilities $3.97 million. The company had $10.0 million principal outstanding under secured convertible notes, carried net at $9.85 million; the notes mature in 2025 and are secured by all company assets. Management stated that cash on hand was sufficient to support operations and meet obligations for at least the next 12 months. The company reported a $137.9 million accumulated deficit.
Material changes versus Q1 2021
- Revenue rose 25% to $5.03 million. Product revenue was essentially unchanged at $3.16 million; service and other revenue more than doubled to $1.87 million.
- Biologics and drug delivery revenue increased 30% to $2.15 million, primarily from higher service revenue associated with new and continuing partnerships. Functional neurosurgery navigation and therapy revenue increased 17% to $2.24 million. Capital equipment and software revenue rose 41% to $0.64 million, though management said hospital capital-equipment purchases remained below pre-pandemic levels.
- Gross margin remained 65%. Higher service revenue, which generally carries higher margins, was offset by a larger excess and obsolete inventory reserve.
- Operating expenses increased: R&D rose 62%, sales and marketing 17%, and G&A 65%. The filing attributes increases primarily to product development, personnel and headcount, share-based compensation, marketing, and insurance costs. Net loss widened 56%.
- Operating cash use increased by $2.14 million year over year. Investing used $0.19 million, while financing provided $0.003 million; the prior-year financing inflow included $46.8 million of net public-offering proceeds.
Outlook, risks and notable items
- No specific revenue, earnings, or cash-flow guidance is provided. Management expects R&D and sales and marketing spending may increase as it develops and commercializes its platforms.
- Management reported about 60 active surgery centers, comparable with the prior-year period, and approximately 45 biologics and drug-delivery partners, versus approximately 25 a year earlier. Broader adoption and commercial success of partner therapies remain uncertain.
- Risks include COVID-19-related disruption or renewed postponement of elective procedures, supply-chain constraints, labor shortages and inflation; the filing also identifies potential effects from the Russia-Ukraine conflict, including supply disruption, higher costs and cybersecurity risks.
- One pharmaceutical customer that is also a stockholder and noteholder and has board representation accounted for 19% of Q1 2022 sales, versus 17% in Q1 2021. Two customers represented 13% and 11% of receivables at quarter-end. Approximately $44.0 million of bank balances exceeded FDIC-insured limits.
- The $10.0 million secured notes bear interest at a rate tied to LIBOR subject to a 2% floor, plus a 2% margin, and may be converted at $6.00 per share, subject to adjustments. A related party is a customer and noteholder, creating a relationship investors may wish to review.
- The filing reports no legal proceedings and no material changes to previously disclosed risk factors other than the added geopolitical-risk disclosure. Management concluded disclosure controls were effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether service-revenue growth, particularly from biologics and drug-delivery partnerships, is recurring and can offset continued operating losses.
- Cash burn trends and the assumptions supporting management’s stated minimum 12-month liquidity outlook.
- Convertible-note terms, maturity, security interests, conversion provisions and the related-party relationship.
- Customer and receivables concentration, including the major pharmaceutical customer’s role in revenue and board relationships.
- Inventory growth and the effect of excess and obsolete inventory reserves on future margins, alongside supply-chain and elective-procedure risks.